DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161.
Oncologist. 2022.
PMID: 35983951
Free PMC article.
Review.